Loading…
Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates
Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new mo...
Saved in:
Published in: | Chembiochem : a European journal of chemical biology 2019-11, Vol.20 (22), p.2876-2882 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3 |
container_end_page | 2882 |
container_issue | 22 |
container_start_page | 2876 |
container_title | Chembiochem : a European journal of chemical biology |
container_volume | 20 |
creator | Renfrew, Anna K. Karges, Johannes Scopelliti, Rosario Bobbink, Felix D. Nowak‐Sliwinska, Patrycja Gasser, Gilles Dyson, Paul J. |
description | Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed.
Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated. |
doi_str_mv | 10.1002/cbic.201900236 |
format | article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02140370v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232045513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</originalsourceid><addsrcrecordid>eNqF0U9P2zAYBnALbQLGduWIInEph3Z-bcdJjyGCgdRpCHVny7HfUKM06ewE1BsfAWnfkE8yV-06ictO_qPf-8jWQ8gp0AlQyr6aypkJozCNBy4PyDEIPh1nkvMPu71gLDsin0J4pJROJYdDcsQBKEtlfky-z7tn7W1IZu5h0b-9vBamd0-6R5vcD_0CWzcs315-Fx5bTEb3xd28iGi-XuFFcuc764eHpNStdTbOhM_kY62bgF926wn5eX01L2_Gsx_fbstiNjYiF3JsJVCwaIHVUIERmZCUV9IYkBprAIS80pkVEnmNFEzKMsksGmvqPKu15ifkYpu70I1aebfUfq067dRNMVObO8pAUJ7RJ4h2tLUr3_0aMPRq6YLBptEtdkNQjHFGRZoCj_T8HX3sBt_GnyjGIaVcsFxGNdkq47sQPNb7FwBVm1LUphS1LyUOnO1ih2qJds__thDBdAueXYPr_8Sp8vK2_Bf-B7yZmSI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2315034286</pqid></control><display><type>article</type><title>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</title><source>Wiley</source><creator>Renfrew, Anna K. ; Karges, Johannes ; Scopelliti, Rosario ; Bobbink, Felix D. ; Nowak‐Sliwinska, Patrycja ; Gasser, Gilles ; Dyson, Paul J.</creator><creatorcontrib>Renfrew, Anna K. ; Karges, Johannes ; Scopelliti, Rosario ; Bobbink, Felix D. ; Nowak‐Sliwinska, Patrycja ; Gasser, Gilles ; Dyson, Paul J.</creatorcontrib><description>Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed.
Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.</description><identifier>ISSN: 1439-4227</identifier><identifier>EISSN: 1439-7633</identifier><identifier>DOI: 10.1002/cbic.201900236</identifier><identifier>PMID: 31102568</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic drugs ; Antitumor agents ; Benzene ; bioinorganic chemistry ; cancer ; Cervical cancer ; Cervical carcinoma ; Cervix ; Chemical Sciences ; Chemotherapy ; Coordination chemistry ; Coordination compounds ; Cymene ; Cytotoxicity ; Drug development ; Drug resistance ; Drugs ; Epithelium ; Exposure ; Ligands ; Medicinal Chemistry ; photoactivated chemotherapy (PACT) ; prodrugs ; Retina ; Retinal pigment epithelium ; Ruthenium ; Ruthenium compounds ; Side effects ; Toluene ; Toxicity</subject><ispartof>Chembiochem : a European journal of chemical biology, 2019-11, Vol.20 (22), p.2876-2882</ispartof><rights>2019 Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</citedby><cites>FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</cites><orcidid>0000-0002-8299-0444 ; 0000-0002-4244-5097 ; 0000-0003-3117-3249 ; 0000-0001-5258-0260 ; 0000-0001-8161-8715</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31102568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02140370$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Renfrew, Anna K.</creatorcontrib><creatorcontrib>Karges, Johannes</creatorcontrib><creatorcontrib>Scopelliti, Rosario</creatorcontrib><creatorcontrib>Bobbink, Felix D.</creatorcontrib><creatorcontrib>Nowak‐Sliwinska, Patrycja</creatorcontrib><creatorcontrib>Gasser, Gilles</creatorcontrib><creatorcontrib>Dyson, Paul J.</creatorcontrib><title>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</title><title>Chembiochem : a European journal of chemical biology</title><addtitle>Chembiochem</addtitle><description>Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed.
Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.</description><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Benzene</subject><subject>bioinorganic chemistry</subject><subject>cancer</subject><subject>Cervical cancer</subject><subject>Cervical carcinoma</subject><subject>Cervix</subject><subject>Chemical Sciences</subject><subject>Chemotherapy</subject><subject>Coordination chemistry</subject><subject>Coordination compounds</subject><subject>Cymene</subject><subject>Cytotoxicity</subject><subject>Drug development</subject><subject>Drug resistance</subject><subject>Drugs</subject><subject>Epithelium</subject><subject>Exposure</subject><subject>Ligands</subject><subject>Medicinal Chemistry</subject><subject>photoactivated chemotherapy (PACT)</subject><subject>prodrugs</subject><subject>Retina</subject><subject>Retinal pigment epithelium</subject><subject>Ruthenium</subject><subject>Ruthenium compounds</subject><subject>Side effects</subject><subject>Toluene</subject><subject>Toxicity</subject><issn>1439-4227</issn><issn>1439-7633</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqF0U9P2zAYBnALbQLGduWIInEph3Z-bcdJjyGCgdRpCHVny7HfUKM06ewE1BsfAWnfkE8yV-06ictO_qPf-8jWQ8gp0AlQyr6aypkJozCNBy4PyDEIPh1nkvMPu71gLDsin0J4pJROJYdDcsQBKEtlfky-z7tn7W1IZu5h0b-9vBamd0-6R5vcD_0CWzcs315-Fx5bTEb3xd28iGi-XuFFcuc764eHpNStdTbOhM_kY62bgF926wn5eX01L2_Gsx_fbstiNjYiF3JsJVCwaIHVUIERmZCUV9IYkBprAIS80pkVEnmNFEzKMsksGmvqPKu15ifkYpu70I1aebfUfq067dRNMVObO8pAUJ7RJ4h2tLUr3_0aMPRq6YLBptEtdkNQjHFGRZoCj_T8HX3sBt_GnyjGIaVcsFxGNdkq47sQPNb7FwBVm1LUphS1LyUOnO1ih2qJds__thDBdAueXYPr_8Sp8vK2_Bf-B7yZmSI</recordid><startdate>20191118</startdate><enddate>20191118</enddate><creator>Renfrew, Anna K.</creator><creator>Karges, Johannes</creator><creator>Scopelliti, Rosario</creator><creator>Bobbink, Felix D.</creator><creator>Nowak‐Sliwinska, Patrycja</creator><creator>Gasser, Gilles</creator><creator>Dyson, Paul J.</creator><general>Wiley Subscription Services, Inc</general><general>Wiley-VCH Verlag</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-8299-0444</orcidid><orcidid>https://orcid.org/0000-0002-4244-5097</orcidid><orcidid>https://orcid.org/0000-0003-3117-3249</orcidid><orcidid>https://orcid.org/0000-0001-5258-0260</orcidid><orcidid>https://orcid.org/0000-0001-8161-8715</orcidid></search><sort><creationdate>20191118</creationdate><title>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</title><author>Renfrew, Anna K. ; Karges, Johannes ; Scopelliti, Rosario ; Bobbink, Felix D. ; Nowak‐Sliwinska, Patrycja ; Gasser, Gilles ; Dyson, Paul J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Benzene</topic><topic>bioinorganic chemistry</topic><topic>cancer</topic><topic>Cervical cancer</topic><topic>Cervical carcinoma</topic><topic>Cervix</topic><topic>Chemical Sciences</topic><topic>Chemotherapy</topic><topic>Coordination chemistry</topic><topic>Coordination compounds</topic><topic>Cymene</topic><topic>Cytotoxicity</topic><topic>Drug development</topic><topic>Drug resistance</topic><topic>Drugs</topic><topic>Epithelium</topic><topic>Exposure</topic><topic>Ligands</topic><topic>Medicinal Chemistry</topic><topic>photoactivated chemotherapy (PACT)</topic><topic>prodrugs</topic><topic>Retina</topic><topic>Retinal pigment epithelium</topic><topic>Ruthenium</topic><topic>Ruthenium compounds</topic><topic>Side effects</topic><topic>Toluene</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Renfrew, Anna K.</creatorcontrib><creatorcontrib>Karges, Johannes</creatorcontrib><creatorcontrib>Scopelliti, Rosario</creatorcontrib><creatorcontrib>Bobbink, Felix D.</creatorcontrib><creatorcontrib>Nowak‐Sliwinska, Patrycja</creatorcontrib><creatorcontrib>Gasser, Gilles</creatorcontrib><creatorcontrib>Dyson, Paul J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Chembiochem : a European journal of chemical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Renfrew, Anna K.</au><au>Karges, Johannes</au><au>Scopelliti, Rosario</au><au>Bobbink, Felix D.</au><au>Nowak‐Sliwinska, Patrycja</au><au>Gasser, Gilles</au><au>Dyson, Paul J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates</atitle><jtitle>Chembiochem : a European journal of chemical biology</jtitle><addtitle>Chembiochem</addtitle><date>2019-11-18</date><risdate>2019</risdate><volume>20</volume><issue>22</issue><spage>2876</spage><epage>2882</epage><pages>2876-2882</pages><issn>1439-4227</issn><eissn>1439-7633</eissn><abstract>Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal‐based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6‐arene)(pta)Cl2] (arene: p‐cymene, toluene, benzene, etc.; pta: 1,3,5‐triaza‐7‐phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA‐type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6‐p‐cymene)pta‐(N3)2], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE‐1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed.
Make a PACT: A diazide complex, [Ru(η6‐p‐cymene)pta(N3)2] (pta: 1,3,5‐triaza‐7‐phosphaadamantane), is inert in water, but slowly releases the azide ligand upon exposure to light. The in vitro cytotoxicity of the complex in the dark and upon light exposure in human cervical carcinoma and noncancerous retinal pigment epithelium cells is investigated.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31102568</pmid><doi>10.1002/cbic.201900236</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-8299-0444</orcidid><orcidid>https://orcid.org/0000-0002-4244-5097</orcidid><orcidid>https://orcid.org/0000-0003-3117-3249</orcidid><orcidid>https://orcid.org/0000-0001-5258-0260</orcidid><orcidid>https://orcid.org/0000-0001-8161-8715</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1439-4227 |
ispartof | Chembiochem : a European journal of chemical biology, 2019-11, Vol.20 (22), p.2876-2882 |
issn | 1439-4227 1439-7633 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_02140370v1 |
source | Wiley |
subjects | Antineoplastic drugs Antitumor agents Benzene bioinorganic chemistry cancer Cervical cancer Cervical carcinoma Cervix Chemical Sciences Chemotherapy Coordination chemistry Coordination compounds Cymene Cytotoxicity Drug development Drug resistance Drugs Epithelium Exposure Ligands Medicinal Chemistry photoactivated chemotherapy (PACT) prodrugs Retina Retinal pigment epithelium Ruthenium Ruthenium compounds Side effects Toluene Toxicity |
title | Towards Light‐Activated Ruthenium–Arene (RAPTA‐Type) Prodrug Candidates |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A33%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Towards%20Light%E2%80%90Activated%20Ruthenium%E2%80%93Arene%20(RAPTA%E2%80%90Type)%20Prodrug%20Candidates&rft.jtitle=Chembiochem%20:%20a%20European%20journal%20of%20chemical%20biology&rft.au=Renfrew,%20Anna%20K.&rft.date=2019-11-18&rft.volume=20&rft.issue=22&rft.spage=2876&rft.epage=2882&rft.pages=2876-2882&rft.issn=1439-4227&rft.eissn=1439-7633&rft_id=info:doi/10.1002/cbic.201900236&rft_dat=%3Cproquest_hal_p%3E2232045513%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4846-d6101ded12f1b1c474603b6cc16aef11e18ba7d46e3fe01c52762decdcf87faa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2315034286&rft_id=info:pmid/31102568&rfr_iscdi=true |